ProCE Banner Activity

Treatment Options From 5 Experts for Advanced Ovarian Cancer: An Online Tool for Patients

Tool

Did you recently receive a diagnosis of advanced ovarian cancer, or has your ovarian cancer come back? Use this interactive tool to see treatment plans from 5 ovarian cancer experts by answering a series of multiple choice questions about your cancer.

Released: May 21, 2020

Expiration: May 20, 2021

Share

Faculty

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Thomas J. Herzog

Thomas J. Herzog, MD

Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bradley Monk

Bradley Monk, MD

Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital Medical
Medical Director, US Oncology Research Network — Gynecologic Program
Co-Director, GOG-Partners
Member, Board of Directors, GOG-Foundation
Phoenix, Arizona

Kathleen N Moore

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma

Provided by

Provided by Postgraduate Institute for Medicine

ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Robert L. Coleman, MD, has disclosed that he has received consulting fees from AbbVie, Aravive, ArQule, AstraZeneca, Cell Medica, Clovis, Cordgenics, Eisai, Geistlich, Genentech, Genmab, ImmunoGen, Janssen, Merck, Mersana , Novocure, OncoMed,Takeda, and Tesaro; fees for non-CME/CE services from Merck and Roche; and funds for research support from AstraZeneca, Clovis, Genentech/Roche, Janssen, and Merck.

Thomas J. Herzog, MD

Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri

Thomas J. Herzog, MD, has disclosed that he has served as a scientific advisor to Clovis, Johnson & Johnson, and Tesaro.

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees from ImmunoGen, Merck, and Mersana Therapeutics.

Bradley Monk, MD

Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital Medical
Medical Director, US Oncology Research Network — Gynecologic Program
Co-Director, GOG-Partners
Member, Board of Directors, GOG-Foundation
Phoenix, Arizona

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma

Kathleen Moore, MD, has disclosed that she has served on advisory boards for Aravive, AstraZeneca, Clovis, Cue Pharma, Genentech/Roche, Merck, Pfizer, OncoMed, Samumed, Tesaro, and VBL.

Additional Information

Program Medium

This program has been made available online.